madman
Super Moderator
SUSTAINED IMPROVEMENT OF LIPID PATTERN AS A RESULT OF LONG-TERM TESTOSTERONE THERAPY (TTH) OVER 13 YEARS IN MEN WITH FUNCTIONAL HYPOGONADISM (2022)
Farid Saad1,2, Ahmad Haider, Karim Haider, Gheorghe Doros, Abdulmaged Traish Consultant, Bayer AG, Berlin, Germany; Research Department, Guld Medical University, Ajman, UAE Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction: Studies reported inconsistent effects of TTh on the lipid profile in men with hypogonadism.
Methods: In a registry of 797 men with symptomatic functional hypogonadism, 394 men (49.5%) received TTh by testosterone undecanoate (TU) injections 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported.
Results: Mean age at baseline: 58.5±6.3 (T-group), 63.2±4.8 (CTRL). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years.
*Total cholesterol (TC) (mmol/L for all lipids) decreased from 8.0±1.1 to 5.1±0.3 (T-group) and increased from 6.6±1.3 to 8.0±1.3 (CTRL) (p<0.0001 for both).
*HDL increased from 1.0±0.3 to 1.6±0.3 (T-group) and decreased from 1.2±0.5 to 0.9±0.4 (CTRL) (p<0.0001 for both).
*The TC: HDL ratio decreased from 9.1±3.6 to 3.3±0.6 (T-group) and increased from 6.5±3.4 to 11.4±5.6 (CTRL) (p<0.0001 for both).
*LDL decreased from 4.4±0.9 to 2.5±0.3 (T-group) and increased from 3.5±1.3 to 4.6±1.5 (CTRL) (p<0.0001 for both).
*Triglycerides (TG) decreased from 3.2±0.6 to 2.2±0.1 (T-group) and increased from 3.0±0.5 to 3.7±0.6 (CTRL) (p<0.0001 for both).
*The LDL: HDL ratio decreased from 5.1±2.5 to 1.7±0.4 (T-group) and increased from 3.6±2.6 to 6.8±4.5 (CTRL) (p<0.0001 for both).
*The HDL:LDL ratio increased from 0.24±0.10 to 0.64±0.13 (T-group) and decreased from 0.41±0.22 to 0.22±0.13 (CTRL) (p<0.0001 for both).
*Non-HDL decreased from 7.0±1.0 to 3.5±0.3 (T-group) and increased from 5.4±1.4 to 7.2±1.4 (CTRL) (p<0.0001 for both).
*Remnant cholesterol decreased from 2.6±0.9 to 1.0±0.3 (T-group) and increased from 1.9±0.9 to 2.6±0.8 (CTRL) (p<0.0001 for both).
*The TG: HDL ratio decreased from 8.4±3.7 to 3.2±0.6 (T-group) and increased from 6.7±3.5 to 11.7±5.7 (CTRL) (p<0.0001 for both).
Conclusion: Long-term treatment with TU in men with functional hypogonadism improved the lipid profile, which worsened in controls.